Mesa Laboratories MLAB Clinical Genomics — Goodwill
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mesa Laboratories in its filing.
Tagged under the XBRL concept us-gaap:Goodwill.
The official record: Mesa Laboratories’s 10-K, filed June 3, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mesa Laboratories's clinical genomics — goodwill.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mesa Laboratories's clinical genomics — goodwill?
- Mesa Laboratories (MLAB) reported clinical genomics — goodwill of $17.12M in Q1 2026.
- How has Mesa Laboratories's clinical genomics — goodwill changed year-over-year?
- Mesa Laboratories's clinical genomics — goodwill increased by 1.2% year-over-year, from $16.93M to $17.12M.
- What is the long-term trend for Mesa Laboratories's clinical genomics — goodwill?
- Over 2 years (2023 to 2026), Mesa Laboratories's clinical genomics — goodwill has grown at a -64.5% compound annual growth rate (CAGR), from $543.21M to $68.39M.
- What does clinical genomics — goodwill mean?
- This represents the intangible asset value recorded when the Clinical Genomics segment was acquired for a price exceeding the fair market value of its identifiable net assets. It reflects the premium paid for expected future synergies, brand reputation, and market position within the genomics industry.